By using a sandwich ELISA, soluble human IL-6 receptor (sIL-6 R) levels were measured in the sera of 20 healthy children and of 25 patients with systemic juvenile rheumatoid arthritis (JRA). In patients with systemic JRA, serum sIL-6 R levels (114.6 +/-37.7 ng/ml) were significantly lower (P < 0.01) than those of healthy children (161.2 +/-45.5 ng/ml). Serum sIL-6 R levels were negatively correlated (r = -0.610, P < 0.001) with serum IL-6 levels measured with the B9 cells. The serum IL-6/sIL-6 R complex was detected using an ELISA based on a monoclonal antibody to IL-6 for capture and on a monoclonal antibody to human sIL-6 R for detection. Healthy controls had little, if any, detectable serum IL-6/sIL-6 R complex (OD 0.024 +/-0.027), while the majority of patients with systemic JRA presented measurable serum IL-6/sIL-6 R complex (OD 0.492 +/-0.546). IL-6 levels estimated in the circulating IL-6/sIL-6 R complexes were in the range of nanograms per milliliter and approximately 20-fold higher than those measured by the B9 cells. Since serum C-reactive protein concentrations were much more correlated with serum levels of IL-6/sIL-6 R complexes (r = 0.713, r2 = 0.51, P < 0.0001) than with the serum IL-6 levels measured with the B9 cells (r = 0.435, r2 = 0.19, P = 0.05), the large quantities […] 
Introduction
IL-6 has multiple biological effects on immune and inflammatory responses (for review see reference 1). It has been shown to induce fever and hepatocyte acute phase response, to enhance proliferation and maturation of B cells as well as immunoglobulin production, and to activate T lymphocyte function. Elevated levels of IL-6 have been found in peripheral blood or other biological fluids in a variety of diseases, including bacterial and viral infections, neoplasia, trauma, and chronic inflammatory diseases (2) .
The receptor mediating the biological activities of IL-6 has been identified as two different membrane glycoproteins, an Receivedfor publication 16 September 1993. 80-kD protein, referred to as the ligand-binding protein (IL-6 receptor [IL-6 R]),' and a 130-kD protein, referred to as the signal transducing protein (3, 4) . cDNA encoding both molecules has been cloned and expressed and its biochemical properties were analyzed (3) (4) (5) . In particular, a genetically engineered truncated form of the 80-kD IL-6 R, lacking the transmembrane and the intracytoplasmatic domains, has been expressed successfully and has been shown to be able to associate with the 130-kD protein in the presence of IL-6 and to mediate IL-6 functions (6). Moreover, a soluble form ofIL-6 R (sIL-6 R) has been purified as a 50-kD protein from human urine (7) and has been shown to be present in human serum and to bind recombinant human IL-6 with a binding affinity similar to that of the entire recombinant IL-6 R molecule (8) .
Juvenile rheumatoid arthritis (JRA) is a clinically heterogenous condition currently divided into different clinkal forms based on symptoms at onset (9) . The systemic form is characterized by chronic arthritis associated with high spiking fever, other systemic features, including evanescent cutaneous rash, hepatosplenomegaly, lymphoadenomegaly, and serositis, and with prominent laboratory evidence of inflammation (9) . The other JRA onset forms are characterized mainly by chronic joint inflammation and are subdivided according to the number ofjoints involved during the first 6 mo of disease in pauciarticular (four or less joints involved) or polyarticular JRA (five or more joints involved) (9) . We have shown previously that serum and synovial fluid IL-6 levels are elevated in patients with JRA during active disease and normalize during remission (10, 11) . In patients with systemic JRA, serum IL-6 levels are much higher than those present in patients with polyarticular or pauciarticular JRA (10, 11) or in patients with adult rheumatoid arthritis (12, 13). In addition, in patients with systemic JRA, synovial fluid IL-6 levels are significantly higher than those present in patients with polyarticular or pauciarticular JRA or in patients with adult rheumatoid arthritis (De Benedetti, F., V. Gerloni, M. Massa, P. Pignatti, R. Caporali, C. M. Montecucco, K. Matsushima, F. Fantini, and A. Martini, manuscript in preparation). Moreover, in systemic JRA, serum IL-6 levels are correlated with the extent and severity ofjoint involvement and with platelet counts (10) . Taken together, these data suggest that IL-6 plays an important role in the pathogenesis of systemic JRA. To better understand the biology of IL-6 and its relation to the sIL-6 R in systemic JRA, in this study we measured serum sIL-6 R levels, evaluated their relation with IL-6 levels, and developed an assay system for the detection of IL-6/sIL-6 R complexes in sera of patients with systemic JRA. as specific optical density obtained by subtracting the nonspecific optical density found in wells coated with PBS alone to the optical density observed in wells coated with the monoclonal antibody 34.1 to human IL-6. To compare the levels of IL-6 present in the IL-6/sIL-6 R complex with the amount ofIL-6 measured by the hybridoma growth factor (HGF) assay (see below), the amount of IL-6 was extrapolated from a standard curve obtained by adding increasing concentrations ofhuman recombinant IL-6 derived from Chinese hamster ovary cells (Genzyme Corp., Cambridge, MA) to a reference serum from a healthy adult control. This serum had 100 ng/ml of sIL-6 R and contained neither detectable IL-6 in the HGF assay nor detectable IL-6/sIL-6 R complex (specific OD 0.000). To obtain acceptable resolution over a wide range of IL-6 concentrations, optical density at 405 nM was read after different times of incubation with the substrate p-nitrophenyl phosphate (see Results and Fig. 5 ). Assayfor IL-6. IL-6 levels were measured using the hybridoma cell line B9 (kindly provided by Dr. L. Aarden, Netherland Red Cross, Amsterdam), as described previously (10) . Chinese hamster ovary cell-derived recombinant human IL-6 (Genzyme Corp.) was used to culture B9 cells and as a standard in the assay.L-6 levels were expressed, unless otherwise indicated, in HGF units-(HGF U), where 1 HGF U is the amount ofIL-6 required to achieve half-maximal proliferation of B9 cells. The conversion from HGF U/ml to pg/ml was performed using the amount of human recombinant IL-6 required to achieve half-maximal proliferation of B9 cells in each assay, that is, -4.5 pg/ml of human recombinant IL-6.
Statistical analysis. Data were analyzed using the Mann-Whitney U test for unpaired samples and the Spearman correlation coefficient.
Results sIL-6 R levels in patients with JRA. Patients with systemic JRA presented serum sIL-6 R levels (114.6±37.7 ng/ml) significantly lower (P < 0.01 ) than those found in healthy children ( 161.2±45.5 ng/ml), while patients with polyarticular or pauciarticular JRA had serum IL-6 R levels (176.7±66.9 and 165.9±51.5 ng/ml, respectively) comparable with those of healthy children (Fig. 1) . To rule out the possibility that the low serum sIL-6 R levels in patients with systemic JRA could be due to the binding of endogenous IL-6 present in patients' sera to the sIL-6 R, thus masking the epitope recognized by the monoclonal antibodies used in the ELISA, we tested the effect of preincubation of normal sera :with exogenous IL-6. As Fig. 2 for two representative sera, the addition of 20 ng/ml of human recombinant IL-6 did not have an effect on the measurement of the sIL-6 R in the assay system. When patients with JRA were divided according to their treatment, no differences in serum sIL-6 R levels were observed (data not shown), thus suggesting that nonsteroidal antiinflammatory drugs, prednisone or methotrexate, do not have a direct effect on the release of sIL-6 R in vivo. No significant correlation ofserum sIL-6 R levels with erythrocyte sedimentation rate values or with C-reactive protein (CRP) concentrations was found in the three JRA onset types (data not shown).
In patients with systemic JRA, serum sIL-6 R levels were negatively correlated (r = -0.610, P < 0.001 ) with serum IL-6 levels measured with the B9 cells (Fig. 3) . To further evaluate the relationship between serum IL-6 and sIL-6 R levels, we measured IL-6 and sIL-6 R levels in serum samples obtained during the' febrile peak from two patients with systemic JRA. As shown in Fig. 4 for one representative patient, the increase in serum IL-6 levels was associated with a decrease in sIL-6 R, whose levels were inversely related to body temperature. sIL-6 R was also found in synovial fluid samples at nanogram per milliliter concentrations with no evident difference among patients with systemic or pauciarticular JRA. As reported previously ( 10, 1 1), while IL-6 levels were much higher in synovial fluids than in the corresponding serum, this was not true for sIL-6 R, suggesting that, unlike IL-6, sIL-6 R is not preferentially produced at, and thus released from, sites of inflammation (Table I) .
Presence of circulating IL-6/sIL-6 R complex in patients with systemic JRA. To identify the circulating IL-6/sIL-6 R complex, we constructed an ELISA based on the use ofa monoclonal antibody to human IL-6 (34.1 ) for capture and a monoclonal antibody to the sIL-6 R (AP-conjugated 22. 3) for detection ofthe IL-6/sIL-6 R complex. To control for possible nonspecific reactivity secondary to the binding of the serum sIL-6 R to plastic, all sera tested were incubated in wells coated with PBS alone and in wells coated with the monoclonal antibody 34.1 to IL-6. A low background was found with no significant differences in the background optical density obtained in wells coated with PBS alone between sera from patients with systemic JRA (n = 25) and sera from healthy controls (n = 12) (0.030±0.031 and 0.021±0.020, respectively; P = 0.79). The SERUM sIL-6 R LEVELS (ng/ml) Figure 3 . Relationship between serum IL-6 and serum sIL-6 R levels in patients with systemic JRA. Serum IL-6 levels were measured using an HGF assay as described in Methods. The dotted line represents the detection limit of the HGF assay. r = -0.618; P < 0.001.
addition of increasing concentrations of human recombinant IL-6 to normal sera resulted in a dose-dependent increase in specific optical density, demonstrating that this assay system is able to detect the IL-6/sIL-6 R complex formed by the binding of exogenous IL-6 to its soluble receptor in human serum. Dose-response curves obtained at different times ofincubation with the substrate for the reference serum are shown in Fig. 5 . As shown in Fig. 6 , healthy children had little ifany detectable IL-6/sIL-6 R complex in their serum (specific OD 0.024±0.027), while the majority of sera from patients with systemic JRA had detectable levels of IL-6/sIL-6 R complex (specific OD 0.492±0.546) with a highly significant difference with sera from healthy controls (P < 0.0001). Comparison of IL-6 levels measured by the HGF assay and those estimated in the IL-6/sIL-6 R complex, as measured by the ELISA, in the same 24 serum samples, lead us to unexpected results. As shown in Table II , in patients with systemic JRA, serum IL-6 levels estimated in the IL-6/sIL-6 R complex were in the range of nanograms per milliliter and were much higher than those measured by the HGF assay (mean ratio IL-6 in IL-6/sIL-6 R complex/IL-6 measured by the HGF assay: 22.4). Of interest, when the same comparison was made for IL-6 levels present in synovial fluid samples, such a difference was not observed (Table II). Moreover, comparison ofthe correlation between IL-6 levels estimated by the two assay systems in sera or in synovial fluids showed that results by the two assay systems are strictly correlated in synovial fluid samples (r2 = 0.78) but are much Figure 2 . Effect of preincubation of normal sera with recombinant human IL-6 (20 ng/ml) on the detection of sIL-6 R. Normal sera were incubated at 37°C for 45 min in the absence or in the presence of 20 ng/ml of recombinant human IL-6 and then tested in the ELISA for sIL-6 R as described in Methods. Results from two representative sera are shown. Background, white box; no IL-6, dotted box; IL-6 (20 ng/ml), striped box. less correlated in serum (r2 = 0.44) (Fig. 7) . Taken together, the data in Table II and Fig. 7 suggest that quantities of IL-6 present in serum are much higher than those estimated by the HGF assay and that the factor(s) interfering with the detection of IL-6 by the HGF assay is present in serum, but not in synovial fluid.
To evaluate the in vivo biological relevance of the large quantities of IL-6 estimated in circulating IL-6/sIL-6 R complexes, we compared the correlation between serum CRP concentrations and the levels ofthe IL-6/sIL-6 R complex with the correlation between serum CRP concentrations and serum IL-6 levels measured with the HGF assay. As shown in Fig. 8 , CRP concentrations were much more correlated with the levels of the circulating IL-6/sIL-6 R complex (n = 24, r = 0.713, r2 = 0.5 1, P < 0.0001 ) than with the serum IL-6 levels measured with the HGF assay (n = 24, r = 0.435, r2 = 0.19, P = 0.05).
Discussion
In this study we have measured serum sIL-6 R levels in patients with JRA and developed an ELISA for the detection of the IL-6/sIL-6 R complex in biological fluids, demonstrating that a high amount of IL-6 circulates as an IL-6/sIL-6 R complex.
The serum sIL-6 R levels found in our age-matched controls are approximately twofold higher than those reported recently by Honda et al. (8) and by Gaillard et al. ( 17) in healthy adults. These differences could be because of differences in the antibodies used or possibly differences in the age ofthe population tested. Indeed, we found that serum sIL-6 R was higher in our age-matched control population (mean level 161.2 ng/ml) than in a group of healthy adults (n = 10; mean level 104.5 ng/ml).
In our study, among patients with JRA, only those with systemic JRA were found to have serum sIL-6 R levels significantly lower than those of healthy controls comparable with age. As far as we know, only two studies are available on serum sIL-6 R levels in human diseases. Patients with HIV infection and patients with multiple myeloma have been reported to have serum sIL-6 R levels significantly higher than healthy controls (8, 17) . These data suggest that different modulation ofthe in vivo levels ofsIL-6 R occurs in different disease conditions. This may possibly be because of quantitative differences in IL-6 production in vivo. Indeed, serum IL-6 levels found in patients with HIV infection or with multiple myeloma (18) (19) (20) are much lower than those present in patients with systemic JRA (10) . A possible role of the increased production of IL-6 in downregulating the levels of sIL-6 R in patients with systemic JRA is suggested by the finding of a negative correlation displayed high optical density in this assay system, demonstrating the presence of elevated serum IL-6/sIL-6 R complex levels. These results suggest strongly that IL-6, or at least part ofit, circulates bound to its soluble receptor in patients with systemic JRA. To the best ofour knowledge, this is the first demonstration of the presence of circulating cytokine/soluble cytokine receptor complexes in human diseases. Our data are consistent with the following hypothesis on the biology of IL-6: IL-6 produced at sites of inflammation (e.g., joints) or produced in the peripheral blood in response to stimuli released by inflammatory sites (e.g., IL-l or TNF-a) binds the serum sIL-6 R and it is vehiculated in the blood as an IL-6/sIL-6 R complex. This binding may protect IL-6 from protease degradation, in a manner similar to what has been described for IL-4 and the soluble IL-4 receptor (24), and/or stabilize IL-6 bioactivity, as has been demonstrated for TNF-a and its soluble receptors (25) . The IL-6/sIL-6 R complex will thus associate with the 1 30-kD signal transducing protein on the surface oftarget cells and mediate IL-6 bioactivities.
Comparison of serum IL-6 levels measured by the HGF assay and those estimated in circulating IL-6/sIL-6 R combetween serum sIL-6 R levels with serum IL-6 levels, measured with the HGF assay, and by the decrease in serum sIL-6 R levels that was associated with the increase in serum IL-6 levels during the febrile peak. The mechanisms of the production of sIL-6 R have not yet been clarified (21, 22) . Nevertheless, our data suggest that two possible mechanisms, not necessarily mutually exclusive, may account for the decrease in the serum sIL-6 R levels in patients with systemic JRA: (a) since IL-6 has been reported to inhibit the expression of the IL-6 R gene both in vivo and in vitro (23), a direct effect of increased in vivo IL-6 production on the expression ofthe IL-6 R gene is conceivable; and (b) the decrease in serum sIL-6 R levels may be a consequence ofa consumption ofcirculating sIL-6 R due to the formation of IL-6/sIL-6 R complexes in the presence of IL-6 and of the subsequent binding and internalization of the complex by target cells expressing the 130-kD signal transducing protein.
This second hypothesis is based on the assumption that circulating IL-6/sIL-6 R complexes are present in patients with systemic JRA. Since the serum soluble form of IL-6 R and the genetically engineered truncated form of IL-6 R have been shown to bind IL-6 with a binding affinity similar to the entire 80-kD molecule (6, 8) and given the serum concentrations of the sIL-6 R found in this study, it is conceivable to hypothesize that IL-6 circulates bound to its soluble receptor. To verify this hypothesis, we constructed an ELISA based on the use of a monoclonal antibody to IL-6 for capture and a monoclonal antibody to sIL-6 R for revealing the presence ofthe IL-6/sIL-6 R complex. Using this approach we found no evidence of circulating IL-6/sIL-6 R complex in healthy controls. How- plexes led us to the unexpected finding that, in patients with systemic JRA, IL-6 was present in nanogram per milliliter amounts in the circulating IL-6/sIL-6 R complexes compared with the few hundreds of picograms per milliliter measured by the HGF assay. Therefore, our data suggest that in systemic JRA, but also possibly in other disease conditions, IL-6 circulates in much higher amounts than those measured by the HGF assay. The possibility that the HGF assay detects only a portion of IL-6 present in human serum is also supported by the consistent finding that IL-6 levels measured with the hepatocyte-stimulating factor assay have been found to be much higher than those measured by the HGF assay in a variety of disease states (26) (27) (28) (29) . More recently, May et al. (30) have demonstrated that the bulk of IL-6 present in peripheral blood circulates in two high molecular weight complexes ( 100-150 and 400-500 kD) and that this IL-6 is not detected by the HGF assay (30) . Of note, among the proteins present in the 100-150-kD complex, a 50-kD material was present, consistent with the molecular weight of the human natural sIL-6 R. Taken together, the discrepancies between serum IL-6 levels measured by the HGF assay and by the hepatocyte-stimulating factor assay (26) (27) (28) (29) , our results, and those of May et al. (30) raise the issue of the biological role of the large quantities of IL-6 present in the peripheral blood. In our study, the strict correlation of serum IL-6 levels measured in the IL-6/sIL-6 R complex ELISA with CRP concentrations in patients with systemic JRA suggests that the high amounts ofIL-6 present in the circulating IL-6/sIL-6 R complex are biologically relevant in vivo, at least as far as the induction by IL-6 of acute phase protein production.
In conclusion, in this study we reported a decrease in sIL-6 R levels in patients with systemic JRA, a disease characterized by a marked increase in serum IL-6 levels. We developed an assay system for detection and measurement of circulating IL-6/sIL-6 R complexes and demonstrated that IL-6 circulates as an IL-6/sIL-6 R complex. We have also found that large quantities ofIL-6, not detected by the HGF assay, are present in the peripheral blood ofpatients with systemic JRA as IL-6/ sIL-6 R complexes, whose in vivo biological relevance is suggested by their strict correlation with serum CRP concentrations.
